These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22419147)

  • 41. Lack of adverse clopidogrel-atorvastatin clinical interaction.
    Saw J; Topol EJ
    Am J Cardiol; 2004 Mar; 93(5):669; author reply 669-70. PubMed ID: 14996608
    [No Abstract]   [Full Text] [Related]  

  • 42. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
    Malmström RE; Ostergren J; Jørgensen L; Hjemdahl P;
    J Intern Med; 2009 Nov; 266(5):457-66. PubMed ID: 19549094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The withdrawal of Baycol (cerivastatin).
    Griffin JP
    Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):177-80. PubMed ID: 11770168
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical pharmacokinetics of cerivastatin.
    Mück W
    Clin Pharmacokinet; 2000 Aug; 39(2):99-116. PubMed ID: 10976657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
    Suh JW; Cha MJ; Lee SP; Chae IH; Bae JH; Kwon TG; Bae JW; Cho MC; Rha SW; Kim HS
    J Atheroscler Thromb; 2014; 21(2):140-50. PubMed ID: 24140730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fatal rhabdomyolysis caused by cerivastatin].
    Scheen AJ
    Rev Med Liege; 2001 Aug; 56(8):592-4. PubMed ID: 11584446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Statin and clopidogrel pharmacological interaction].
    Leoncini M; Toso A; Maioli M; Bellandi F
    G Ital Cardiol (Rome); 2013 Sep; 14(9):574-84. PubMed ID: 23903277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
    Vinholt P; Poulsen TS; Korsholm L; Kristensen SR; Hallas J; Damkier P; Mickley H
    Thromb Haemost; 2005 Aug; 94(2):438-43. PubMed ID: 16113837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
    Wenaweser P; Windecker S; Billinger M; Cook S; Togni M; Meier B; Haeberli A; Hess OM
    Am J Cardiol; 2007 Feb; 99(3):353-6. PubMed ID: 17261397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.
    Clarke TA; Waskell LA
    Drug Metab Dispos; 2003 Jan; 31(1):53-9. PubMed ID: 12485953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clopidogrel-statin interaction: a mountain or a mole hill?
    Steinhubl SR; Akers WS
    Am Heart J; 2006 Aug; 152(2):200-3. PubMed ID: 16875897
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.
    Marusic S; Lisicic A; Horvatic I; Bacic-Vrca V; Bozina N
    Int J Clin Pharm; 2012 Dec; 34(6):825-7. PubMed ID: 23076661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
    Rowan C; Brinker AD; Nourjah P; Chang J; Mosholder A; Barrett JS; Avigan M
    Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):301-9. PubMed ID: 19206087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atorvastatin-clopidogrel interaction.
    Martin PT; Denman R
    Circulation; 2003 Jun; 107(24):e223; author reply e223. PubMed ID: 12821599
    [No Abstract]   [Full Text] [Related]  

  • 58. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
    Shitara Y; Hirano M; Sato H; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proton pump inhibitors and clopidogrel.
    Gaglia MA; Waksman R
    Cardiovasc Ther; 2010 Jun; 28(3):169-76. PubMed ID: 20345494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinically relevant interaction between clopidogrel and proton pump inhibitors].
    Alban S; Dingermann T; Griese N; Kämmerer W; Schubert-Zsilavecz M; Schulz M; Trenk D; Zagermann-Muncke P
    Pharm Unserer Zeit; 2009; 38(4):370-1. PubMed ID: 19572357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.